ad image

Keynote-048 Trial

1 / 1
Merck & Co.
Phase III Trial

KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial

Merck & Co.

PR-M07-18-NI-093Jul 27, 2018
1 / 1